A stand-alone webinar event will focus on the role that cannabis medicines can play in relieving back pain.
This new field of medicine can offer life-changing help to those patients who find that traditional pain medicines and clinical intervention are no longer helping or have unpleasant side effects.
The discussion will explore the potential benefits of the addition of cannabis medicines into a chronic pain management regime for this diverse patient group.
Including injury, wear and tear, musculoskeletal disorders such as scoliosis, axial spa or spina bifida or as a consequence of another underlying health condition such as multiple sclerosis, fibromyalgia, arthritis, Parkinson’s disease or cancer.
The healthcare professionals taking part have many years experience between them in complex pain management and expertise in the treatment of back pain for a variety of conditions.
Dr Anthony Ordman – consultant pain specialist at Integro Clinics and former president of the Pain Medicine Section of the Royal Society of Medicine
Dr Basil Almahdi – consultant pain specialist at Complex Spine Clinics London
Dr Brian Hammond, PhD – chiropractor & osteopath, CEO National Back Pain Association (BackCare)
The event, hosted by The National Back Pain Association (more commonly known as BackCare or BackPain UK) and Integro Medical Clinics will take place on Thursday 25 May from 7pm-8.30pm.
Science finds a way for medical cannabis to relieve pain without side effects
Researchers have developed a molecule that allows THC to fight pain without the side effects.
Scientists may have developed a molecule which could allow medical cannabis to provide pain relief without any side effects.
Many people live with chronic pain, and in some cases, cannabis can provide relief.
But the drug also can significantly impact memory and other cognitive functions.
Now, researchers have developed a peptide that, in mice, allowed THC to fight pain without the side effects.
According to the US Centres for Disease Control and Prevention (CDC) around 20 percent of adults in the states experienced chronic pain in 2019.
Previously, researchers identified two peptides [molecules which are made up of amino acids] that disrupt an interaction between a receptor that is the target of THC and another that binds serotonin, a neurotransmitter that regulates learning, memory and other cognitive functions.
When the researchers injected the peptides into the brains of mice, the mice had fewer memory problems caused by THC.
Now, this team, led by Rafael Maldonado, David Andreu and colleagues, has gone one step further to improve these peptides to make them smaller, more stable, orally active and able to cross the blood-brain barrier.
Based on data from molecular dynamic simulations, the researchers designed two peptides that were less than half the length of the original ones but preserved their receptor binding and other functions.
They also optimised the peptide sequences for improved cell entry, stability and ability to cross the blood-brain barrier.
Then, the researchers gave the most promising peptide to mice orally, along with a THC injection, and tested the mice’s pain threshold and memory.
Mice treated with both THC and the optimised peptide reaped the pain-relieving benefits of THC and also showed improved memory compared with mice treated with THC alone.
Importantly, multiple treatments with the peptide did not evoke an immune response.
Reporting in the American Chemical Society’s Journal of Medicinal Chemistry, researchers say that these findings suggest the optimised peptide is an ideal drug candidate for reducing cognitive side effects from cannabis-based pain management.
The abstract that accompanies this paper can be viewed here.
Study: Novel CBD strain shows promising effects on pain
A novel strain of CBD has been shown to have positive pain-relieving effects in studies on mice.
A novel strain of CBD has been shown to have positive pain-relieving effects in mice.
A US study has generated promising results around the pain-relieving capabilities of a novel CBD analog in animals with chemotherapy-induced peripheral neuropathy (CIPN).
CIPN is a common side effect of certain cancer treatments that damage peripheral nerves, which carry sensory information to the arms, legs, and brain.
The severe pain manifests in different ways in human patients but involves tingling or burning sensations and numbness, weakness, or discomfort in the limbs.
Studies have shown that while CBD reduces pain sensation in animals, its ability to do so in humans is limited by low bioavailability.
New work by scientists at the Lewis Katz School of Medicine at Temple University, suggests this obstacle may be overcome by a novel CBD analog known as KLS-13019, developed by the Pennsylvania-based biopharmaceutical company Neuropathix.
In previous work in cell models, it was found to be more potent than CBD, and studies in animals suggested it had improved bioavailability.
In a series of experiments designed to gauge animals’ pain responses, researchers found that pain sensitivity was greatly reduced in animals with CIPN that were treated with KLS-13019 or CBD.
KLS-13019 further reversed sensitivity to painful stimuli in animals in which peripheral neuropathy was already established, an effect that was not observed in CBD-treated animals.
Dr Sara Jane Ward, PhD, Assistant Professor of Pharmacology at the Katz School of Medicine and senior investigator on the new study, commented: “In a mouse model of chemotherapy-induced peripheral neuropathy (CIPN), we’ve been able to show for the first time that KLS-13019 works as well as, if not better than, CBD in preventing the development of neuropathy and reversing pain sensitivity after pain has been established.”
Earlier studies have also hinted at the possibility that CBD is able to reduce opioid craving in patients with opioid use disorder.
While Dr Ward and colleagues did not find evidence supporting a role for CBD in reducing opioid craving, they did observe significantly reduced opioid-seeking behaviour in KLS-13019-treated animals.
“This tells us that KLS-13019 has benefits beyond its ability to alleviate pain,” Dr Ward added.
Researchers suspect that while sharing a mechanism with CBD for pain relief, KLS-13019 may have an additional mechanism of action, one that breaks up the pathways reinforcing opioid use.
Dr Ward and her team also plan to test the ability of KLS-13019 to alleviate other types of pain, beyond CIPN.
The findings were published online in the British Journal of Pharmacology.
Why are more seniors turning to CBD?
Three quarters of people over the age of 55 would be open to considering cannabis medication if it was offered to them.
Elderly people experience a wide range of health issues, including chronic pain, heart disease, arthritis, osteoporosis and Alzheimer’s.
CBD oil has been known to help manage pain, inflammation and promoting cell repair, but research has shown that natural remedies – like CBD – can also help strengthen the bones if the older generation has Osteoporosis, and even promote the healing process if a fracture does occur.
Heart disease is the most common condition amongst older adults and the number one cause of death for this age group.
CBD may be an effective and natural treatment for high blood pressure as studies found that the antioxidant properties of CBD may help reduce cardiac inflammation. By reducing blood pressure and repeat inflammation, CBD can significantly improve the overall heart health and serve as a preventive measure against serious health conditions.
Experts suggest sleeping disorders, like insomnia, can also be cured by CBD by calming the user and naturally promoting a healthier sleeping patter for seniors, rather than them turning to sleeping medications.
Latest research from Open Cannabis, a new campaign created to educate the public, suggests almost three quarters of people over the age of 55 would be open to considering cannabis medication if it was offered to them, as it may have the potential to treat a wide spectrum of common health conditions they encounter.
The effects of old age are felt most by the physical strength of the elderly – aching joins, back pain, and tired muscles all form their common experience, each depriving the vast majority of this demographic the joy of walking and working.
According to the British Medical Journal, the proportion of people over the age of 75 who suffer daily with chronic pain could be as high as 60 per cent.
The elderly would use strong pain relief tablets such as paracetamol or ibuprofen to help ease their pain, however the use of CBD oil is a natural alternative which has no known side effects as opposed to the majority of harsh pharmaceuticals.
CBD research also shows how it has been well tolerated at extremely high doses, removing worry of potential toxic concerns, although speak to a doctor or healthcare professional who may be able to recommend the right dosage.
Cannabis oil has become more popular in recent years since is it vegan and organically sourced, as animal products are rarely used in CBD products.
Seniors in the UK cannot expect to possess a prescription for CBD at this moment in time, although the remedy can be bought from health and wellbeing shops or online from a trusted retailer.
Overall, the demand for CBD products has grown rapidly, and seniors are the perfect candidates for use, as their bodies need that extra bit of support, which CBD oil can give over harsh pharmaceuticals that could cause harsh side effects.
Introducing our new B2B title
- Six big cannabis sector stories you might have missed this week
- Science finds a way for medical cannabis to relieve pain without side effects
- Dutch Government to supply medical cannabis for UK patients until 2022
- Novel food regulations look set to dramatically shrink the CBD sector
- Calls for workplace cannabis drug-testing to be scrapped for nurses
- What is cachexia – and could cannabis be a potential treatment?
News10 months ago
NHS lines up cannabis medicine manufacturing
News6 months ago
Community extends support to cannabis icon Rick Simpson
Case Studies1 year ago
CBD oil and fibromyalgia – a case study
Feature11 months ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
Insight7 months ago
I’ve gone from a wheelchair to walking thanks to cannabis
News8 months ago
Cancer survivor claims cannabis oil helped her beat brain tumour
Industry4 months ago
“Game changer” for the sector: First cannabis company expected to list on LSE next month
News8 months ago
“I’m not a bad person” – chronically ill woman convicted of growing medical cannabis